Trials / Terminated
TerminatedNCT03358290
Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of JTE-051 Administered for 12 Weeks in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR-PS)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Akros Pharma Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-051 administered for 12 weeks in subjects with moderate to severe plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JTE-051 | Active drug tablets containing JTE-051 |
| DRUG | Placebo | Placebo tablets identical in appearance to the active drug tablets |
Timeline
- Start date
- 2017-11-10
- Primary completion
- 2018-10-29
- Completion
- 2018-10-29
- First posted
- 2017-11-30
- Last updated
- 2021-08-06
- Results posted
- 2021-08-06
Locations
16 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03358290. Inclusion in this directory is not an endorsement.